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ABSTRACT 
Cisplatin and other platinum derivatives like carboplatin and oxaliplatin are widely used chemotherapeutic agents used in the treatment of 
solid tumors including head and neck, ovarian and testicular germ cell tumors. Cisplatin is also used successfully in the tre atment of paediatric 
malignancies, such as medulloblastoma and osteogenic sarcoma. In most recent treatment schedules, the drug is used in combination with 
other cytotoxic agents such as otoposide, doxorubicine, paclitaxel, 5-fluorouracil, gemcitabine, vinblastine, bleomycin and others. It is one of on 
the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in health system. This comprehensive 
review highlights the physicochemical properties of cisplatin and related platinum based drugs, uses of platinum, either alone or in 
combination with other drugs for the treatment of various human cancers and also discuss about various Potential protective strategies against 
cisplatin-induced cytotoxicities. A special attention is given to it’s molecular mechanisms of action, historical background, undesirable side 
effects & future prospective.  
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INTRODUCTION 
Platinum based drug Cisplatin also called as ‘The Penicillin of 
cancer’ is the first  potent drug used in the chemotherapy of 
cancer. Food and Drug Administration (FDA) in 1978, 
approved cisplatin as leading anti- cancer drug for several 
types of cancer, such as bladder cancer, ovarian cancer, 
cervical cancer non-small cell lung cancer, squamous cell 
carcinoma of the head & neck and testicular cancer.1  Even 
with the advancement of new therapies in the past decades, 
the use of cisplatin remains strong.2–4 Cisplatin is one of the 
most remarkable successes in ‘the war on cancer.’ Although 
the profound effects of cisplatin in different types of the 
cancer, the patients experience severe side effects such as 
vomiting and nausea, myelosuppression, neurotoxicity, 
ototoxicity and nephrotoxicity that limit its use.5  
Historical perspective of cisplatin discovery 
This compound was first synthesized in 1840 by Peyrone 
and known for a long time as Peyrone Chloride.6 However, its 
antineoplastic activity remained unnoticed for 120 years. 
The physicist Barnett Rosenberg accidently observed that 
cisplatin inhibited the proliferation of Escherichia coli cells 
and provoked filamentous growth of bacterial cells.7 Since its 
biological properties were first tested on tumors in 1971. 
The involvement of inorganic metal based compounds was 
very limited until the discovery of potent anti-cancer activity 
in certain platinum compounds by Rosenberg and Van Camp 
in 1969.8 The world of clinical oncology was initially not too 
enthusiastic about the potential usefulness of the first 
platinum based drug; this was perhaps not surprising as 
medical scientists tend to regard all heavy metal compounds 
as non-selective poisons. However, the platinum discovery 
heralded the arrival of metal co-ordination compounds as a 
new class of potential antitumor drugs and some researchers 
such as late Sir Alex Haddow at the Institute of Cancer 
Research, London, persevered with platinum in the belief 
that such a new group would emerge from Rosenberg’s 
discovery. After some toxicological problems the first 
platinum drug, cisplatin, has now become a useful first line 
treatment for several tumours and has been approved by the 
U.K. and U.S.A. governments.9, 10 
Chemistry of Cisplatin 
Unlike most cancer therapy drugs, which are usually complex 
organic compounds, cisplatin is a simple inorganic molecule 
containing a central atom of platinum surrounded by two 
chloride atoms and two ammonia molecules in the cis 
position, see figure-1.11 
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Figure 1: Chemical Structure of Cisplatin. 
 It is a white powder with the molecular formula PtCl2H6N2.11 
it is a metallic (platinum) coordination compound with a 
square planar geometry that is a white or deep yellow to 
yellow-orange crystalline powder at room temperature. It is 
slightly soluble in water and soluble in dimethylprimanide 
and N, N-dimethylformamide. Cisplatin is stable under 
normal temperatures and pressures, but may transform 
slowly over time to the trans-isomer.10, 11 It is a small, 
uncharged platinum complex with two chloride ligands. The 
compound is rather stable and inert as long as it is in a high 
chloride environment, such as in the blood stream (150 mM). 
When entering the cell, where chloride concentrations are as 
low as 5 mM, the ligands of cisplatin are sequentially 
exchanged by water molecules forming so-called highly 
reactive positively charged aqua complexes, which can be 
either monohydrated [Pt(NH)Cl(OH)] or dihydrated 
[Pt(NH)(OH)]. Both positively charged hydrated forms of 
cisplatin are electrostatically attracted by negatively charged 
macromolecules in the cell, such as DNA, and thereby, 
facilitating the reaction with nucleophilic centers like the N7 
atom of Due to the presence of two potentially reactive sites, 
cisplatin is a bifunctional drug enabling the formation of 
covalent crosslinks between two molecules. guanine.9 
Cisplatin has a molecular weight of 301.1 gm/mol, a density 
of 3.74 g/cm3, a melting point of 270° C, a log Kow of -2.19 
and a water solubility of 2.53 g/L at 25° C.11 
Use of Cisplatin in cancer treatment 
cisplatin has become one of the most used drugs in the 
treatment of solid tumors of epithelial origin. Although 
cisplatin has been a mainstay for testicular cancer therapy. It 
is also commonly used to treat ovarian, cervical, bladder, and 
non-small cell lung carcinoma as well as head and neck 
cancers. Cisplatin is also successfully used in the treatment of 
paediatric malignancies, such as medulloblastoma and 
osteogenic sarcoma.12 In most recent treatment schedules, 
the drug is used in combination with other cytotoxic agents 
such as otoposide, paclitaxel, doxorubicine, 5-fluorouracil, 
gemcitabine, vinblastine, bleomycin and other.13-15 
Synthesis & Production of cisplatin 
Preparation of cisplatin was reported in the 1840s.6,10 The 
synthesis of cisplatin starts from potassium 
tetrachloroplatinate. The tetraiodide is formed by reaction 
with an excess of potassium iodide. Reaction 
with ammonia forms K2[PtI2(NH3)2] which is isolated as a 
yellow compound. When silver nitrate in water is added 
insoluble silver iodide precipitates and K2[Pt(OH2)2(NH3)2] 
remains in solution. Addition of potassium chloride will form 
the final product which precipitates.16 See Figure 2, 
 
 
Figure 2: Synthesis of Cisplatin. 
In 2009, cisplatin was produced by eleven manufacturers 
worldwide, including four in India, three in Central and 
South America, two in Europe, one each in China and Mexico, 
and none in the United States.17 It was available from 35 
suppliers; including 23 U.S. suppliers and seven drug 
products with cisplatin as the active ingredient were 
produced by five pharmaceutical companies.18, 19 
Mechanisms of cytotoxic action 
The exact molecular mechanism of the cytotoxicity induced 
by cisplatin is still unknown, but it is generally accepted that 
the primary target for the drug is nuclear DNA. Cisplatin 
becomes activated once it enters the cell. In the cytoplasm 
the chloride atoms on cisplatin are displaced by water 
molecules. This hydrolyzed product is a potent electrophile 
that can react with any nucleophile, including the sulfhydryl 
groups on proteins and nitrogen donor atoms on nucleic 
acids. Cisplatin binds to the N7 reactive center on purine 
residues and as such can cause deoxyribonucleic acid (DNA) 
damage in cancer cells, blocking cell division and resulting in 
apoptotic cell death. The 1,2-intrastrand cross-links of 
purine bases with cisplatin are the most notable among the 
changes in DNA. These include the 1,2- intrastrand d(GpG) 
adducts 1,2-intrastrand d(ApG) adducts representing about 
90% and 10% of adducts, respectively. 1,3-intrastrand 
d(GpXpG) adducts and other adducts such as inter-strand 
crosslinks and nonfunctional adducts have been reported to 
contribute to cisplatin's toxicity.20, 21 There are several 
reports on the interaction of cisplatin with RNA, proteins 
involved in antioxidant systems, cell signalling, cell 
metabolism and mitochondrial DNA. Those reactions may 
induce apoptosis, necrosis or autophagy, as cell death 
pathways.22- 24 
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Factors limiting the therapeutic efficacy of 
cisplatin 
In spite of the clinical success of cisplatin, repetitive 
treatment often has to be discontinued at a certain stage. The 
two limiting factors for a successful application of cisplatin 
are acquired or intrinsic drug resistance of the tumor and 
severe side effects in normal tissues, mainly in the kidney, in 
the inner ear and in the peripheral nerves.25, 26 
Cisplatin resistance 
The molecular mechanism of cisplatin resistance has been 
studied extensively, which may involve decreased uptake or 
increased efflux of cisplatin, neutralization of cisplatin by 
glutathione and other sulfur-containing molecules, increased 
DNA repair, and defective apoptotic signaling in response to 
DNA damage.27, 28 
Cisplatin side effects 
Cisplatin treatment has been associated with several toxic 
side effects including nephrotoxicity, hepatotoxicity and 
Cardiotoxicity.29, 30  Many cardiac events have been reported 
in many case reports including electro-
cardiographicchanges, arrhythmias, myocarditis, 
cardiomyopathy and congestive heart failure.31 Decrease in 
antioxidant defense system is reported due to oxidative 
stress through the generation of reactive oxygen species, 
including antioxidant enzymes and non enzymatic molecules, 
reduced glutathione, are major alterations in the cisplatin 
toxicity.32 
Nephrotoxicity 
Nephrotoxicity (kidney damage) is a major concern. 
Nephrotoxicity is a dose-limiting side effect.33 Cisplatin 
causes tubular cell death by either necrosis or apoptosis 
depending upon the concentration and duration of exposure 
of drug.34 The dose is reduced when the patient's creatinine 
clearance (a measure of renal function) is reduced. Adequate 
hydration and diuresis is used to prevent renal damage. The 
nephrotoxicity of platinum-class drugs seems to be related 
to reactive oxygen species and in animal models can be 
ameliorated by free radical scavenging agents 
(e.g., amifostine). Recent literature indicates that reactive 
oxygen species (ROS) play important roles in the progression 
of kidney damage.35, 36 Oxidative stress caused by alterations 
in redox homeostasis can directly exert renal parenchymal 
damage and may intensify renal microvascular and 
functional dysregulation.37  Then, increased oxidative stress 
in the kidney leads to deterioration of the renal function, 
inflammation, and apoptosis.38 
Neurotoxicity (nerve damage) 
Despite favorable anti-tumor properties, platinum drugs can 
cause serious neurotoxicity. Common neurological side 
effects of cisplatin include visual perception and hearing 
disorder, which can occur soon after treatment begins. While 
triggering apoptosis through interfering with DNA 
replication remains the primary mechanism of cisplatin, this 
has not been found to contribute to neurological side 
effects.39, 40 Recent studies have shown that cisplatin 
noncompetitively inhibits an archetypal, membrane-bound 
mechanosensitive sodium-hydrogen ion transporter known 
as NHE-1. It is primarily found on cells of the peripheral 
nervous system, which are aggregated in large numbers near 
the ocular and aural stimuli-receiving centers. This 
noncompetitive interaction has been linked to 
hydroelectrolytic imbalances and cytoskeleton alterations, 
both of which have been confirmed in vitro and in vivo.41 
GIT toxicity 
Nausea, vomiting and anorexia are common side effect of 
cisplatin treatment. An antiemetic regimen is normally 
incorporated. Treatment has been improved by the addition 
of 5-HT-3 receptor antagonists, which now constitute a basis 
of every antiemetic regime together with steroids.42 Changes 
in diet such as eating several small meals or limiting activity 
may help lessen some of these effects. 
Ototoxicity (hearing loss) 
Ototoxicity is one dose limiting side effect of cisplatin. there 
is at present no effective treatment to prevent this side effect, 
which may be severe. Audiometric analysis may be necessary 
to assess the severity of ototoxicity. Other drugs (such as the 
aminoglycoside antibiotic class) may also cause ototoxicity, 
and the administration of this class of antibiotics in patients 
receiving cisplatin is generally avoided. The ototoxicity of 
both the aminoglycosides and cisplatin may be related to 
their ability to bind to melanin in the stria vascularis of the 
inner ear or the generation of reactive oxygen species.43 
Electrolyte disturbance 
Cisplatin can cause hypomagnesaemia, hypokalaemia and 
hypocalcaemia. The hypocalcaemia seems to occur in those 
with low serum magnesium secondary to cisplatin, so it is 
not primarily due to the cisplatin.41 
Hemolytic anemia 
Anaemia can be developed after several courses of cisplatin. 
It is suggested that an antibody reacting with a cisplatin-red-
cell membrane is responsible for hemolysis.44, 45 
Other Organ Toxicity 
Other cisplatin-induced organ toxicities such as 
myelosuppression, allergic reactions and some reproductive 
toxic effects have also been reported.46 
Potential protective strategies against cisplatin-
induced cytotoxicities 
For years, various approaches have been attempted to curtail 
cisplatin side effects. Several pharmacological compounds 
are currently being tested to enhance protection during 
cisplatin treatment.   One strategy is to synthesize and screen 
for novel cisplatin analogues that have lower toxicity in 
normal tissues. In this direction, several cisplatin analogues, 
such as carboplatin and oxaliplatin, have been identified with 
less severe side effects.47 Unfortunately, both of them have 
severe and dose-limiting side effects as well. Carboplatin and 
especially oxaliplatin have prominent neurotoxic effects, but 
do not induce considerable ototoxicity or nephrotoxicity.48 In 
contrast to oxaliplatin, carboplatin additionally displays 
prominent toxicity in the hematopoietic system. The 
mechanisms of the noted differences in side effects are still 
not fully understood. Another approach that has been used 
with some success is to hydrate the patients during cisplatin 
treatment.49, 50  OCT2 inhibitors such as cimetidine have been 
shown to protect against cisplatin induced renal toxicity in 
mice without interfering with the antineoplastic actions of 
cisplatin.51, 52  More recently, Kim HJ, et al. (2015),53 reported 
that administration of glutamine, a substrate for glutathione 
synthesis, reduced cisplatin associated pathological changes 
in HK-2 cells and in rats via reduced expression of OCT2. 
Whereas these findings are promising, one possible 
drawback of pharmacological inhibition of OCT2 may be 
inhibition of cisplatin uptake by cancer cells, which are the 
target of cisplatin treatment, and hence, this may reduce the 
antineoplastic action of cisplatin.  El Awady et al (2011),54   
investigated that administration of silymarin, a potent 
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antioxidant, in a rat model of cisplatin-induced cardiac 
toxicity, antagonized the depletion of glutathione and 
superoxide dismutase and consequently reduced the 
concentration of cardiac damage marker enzymes induced 
by cisplatin, towards normal level, resulting in cardiac 
protection. Also, treatment with the hydrogen sulfide (H2S) 
donor sodium hydrosulfide (NaHS) and garlic-derived diallyl 
disulfide (a natural source of H2S) has been reported to 
enhance the activity of renal antioxidant enzymes and 
reduced oxidative stress thereby attenuating cisplatin-
induced renal toxicity in rats.55, 56 Furthermore, combination  
treatment of tumor-bearing mice and rats with vitamin C and 
cisplatin significantly increased endogenous antioxidant 
levels, decreased tissue lipid peroxidation and well protected 
the kidney, liver and testes against cisplatin-induced toxicity 
compared to cisplatin treatment alone.57 NaHS 
administration activated endogenous antioxidant defense 
system and protected proximal tubular cells from apoptosis 
in a rat model of cisplatin-induced renal toxicity.58 Recently, 
H2S related therapy has been proven successful in treating 
other forms of cellular stress due to myocardial ischemia-
reperfusion injury and acute kidney injury.59, 60  Moreover, 
Strutynska NA, et al. (2013),61 observed that H2S treatment 
prevented opening of the MPTPs in a rat model of 
spontaneous hypertension, suggesting its application in 
cisplatin-induced toxicity. Other protective pharmacological 
agents that may not interfere with the anticancer action of 
cisplatin could be used if they are tested and proven to 
ameliorate cisplatin-induced toxicity. Despite these efforts, 
the side effects of cisplatin, particularly nephrotoxicity, 
remain a major factor that limits the use and efficacy of 
cisplatin in cancer therapy. 
Future perspectives 
Over the last several decades, many researchers, have been 
developing new formulations of cisplatin in an effort to 
reduce its side effects. The best way to do this is through the 
use of nanoparticles to better target cisplatin to cancer cells. 
Better targeting cancer drugs are important so they don’t 
attack non-cancerous tissue. One such nanoparticle 
formulation being commercially developed is Lipoplatin. 
This formulation encloses cisplatin in a shell called 
a liposome, which is similar in structure to the walls of 
human cells. As a result, it floats in the bloodstream for 
longer and gets trapped selectively in tumours but not 
normal tissue. And it doesn’t stop there. Novel nanoparticle 
formulations of cisplatin using exotic materials are also being 
developed, although these are much further away from being 
ready for human testing. To date, cisplatin has been attached 
to carbon nanotubes, gold nanoparticles and even spaghetti 
ball-like polymers called dendrimers. 
CONCLUSIONS 
Cisplatin is currently one of the most widely-used 
chemotherapeutic agents against various malignancies. This 
drug has revolutionised the treatment of many types of 
cancer, especially testicular, and remains as critically 
important now as when it was first discovered. Its clinical 
application is limited, however, by inherent renal and cardiac 
toxicities and other side effects, of which the underlying 
mechanisms are only partly understood.  Therefore, 
combinatorial strategies such as cisplatin plus H2S-related 
therapy or cisplatin with taurine, which target ROS 
generation, inflammatory and apoptotic pathways in 
cisplatin-induced toxicity may offer the best chance of 
clinically meaningful prevention. However, there are very 
few clinical trials reporting on combinatorial therapies to 
prevent these side effects, and hence require additional 
research. More importantly, there is the need to test 
pharmacological (and genetic) approaches to cytoprotection 
in experimental or natural tumor-bearing animals to 
enhance their application to cisplatin treatment in oncology. 
Identification of novel interventions aimed at minimizing 
cisplatin-induced cytotoxicities while enhancing its 
antineoplastic efficacy would open new avenues to enhance 
cisplatin-based cancer therapy. 
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